Below you can find some of the most important clinical guidelines published in 2014. Please note that this is not an exhaustive list.
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology
Anxiety disorders and OCD
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
Postoperative Delirium in Older Adults: Best Practice Statement from the American Geriatrics Society
NICE Guidelines – Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care
Indication: Obesity and overweight treatment
- 30 kg/m or greater (obese) or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Limitations of Use:
The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established
Available: early 2015
- Do not use in patients with narcolepsy
Warnings and precautions
- Daytime somnolence: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness
- Need to evaluate for co-morbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment.
- Nighttime “sleep-driving” and other complex behaviors while out of bed and not fully awake. Risk increases with dose, with use of CNS depressants, and with alcohol .
- Depression: Worsening of depression or suicidal thinking may occur. Risk increases with dose. Immediately evaluate any new behavioral changes
- Compromised respiratory function: Effect on respiratory function should be considered
- Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms: Risk increases with dose .